CSPC Innovation Pharmaceutical Co., Ltd.

Equities

300765

CNE100003K04

Food Processing

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
34.27 CNY +1.63% Intraday chart for CSPC Innovation Pharmaceutical Co., Ltd. +14.62% +12.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
China's drugmakers can't sell mRNA shots but haven't quit yet RE
CSPC Innovation Pharmaceutical Co., Ltd. Approves Cash Dividend for 2023 CI
Tranche Update on CSPC Innovation Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 21, 2023. CI
CSPC Innovation Pharmaceutical Co., Ltd.(XSEC:300765) added to FTSE All-World Index CI
CSPC Innovation Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
CSPC Innovation Pharmaceutical's Attributable Profit Rises 4%; Shares Jump 6% MT
CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CSPC Baike's 2023 Profit Reaches 859 Million Yuan MT
CSPC Innovation Pharmaceutical Co., Ltd. announced a financing transaction CI
Tranche Update on CSPC Innovation Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 21, 2023. CI
CSPC Innovation Pharmaceutical Co., Ltd.(SZSE:300765) added to Shenzhen Stock Exchange Component A Share Index CI
CSPC Innovation Pharmaceutical Co., Ltd.(SZSE:300765) added to Shenzhen Stock Exchange Component Index CI
CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on CSPC Innovation Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 21, 2023. CI
CSPC Innovation Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 421.8 million worth of its shares. CI
CSPC Innovation Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China’s NMPA Accepts CSPC Pharma’s License Application for Asthma Drug MT
CSPC Innovation Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Cspc Innovation Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on April 27, 2023 CI
CSPC Innovation Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022 CI
CSPC Innovation Pharmaceutical Co., Ltd. Approves Board Appointments CI
CSPC Innovation Pharmaceutical Co., Ltd. Proposes Final Dividend for 2022 CI
CSPC Shengxue Glucose Co.,Ltd. announced that it expects to receive CNY 260 million in funding from CSPC Innovation Pharmaceutical Co., Ltd. CI
Chart CSPC Innovation Pharmaceutical Co., Ltd.
More charts
CSPC Innovation Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of functional foods. The Company's main products include caffeine products, vitamin products and other functional foods. The Company’s caffeine products are mainly caffeine, including a small amount of theophylline, aminophylline and theobromine. The vitamin products are mainly vitamin C tablets, including a small amount of vitamin C drinks. The Company mainly distributes its products both in the domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.27 CNY
Average target price
40.1 CNY
Spread / Average Target
+17.00%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300765 Stock
  4. News CSPC Innovation Pharmaceutical Co., Ltd.
  5. CSPC Innovation Pharmaceutical's Attributable Profit Rises 4%; Shares Jump 6%